AbClon Inc. (KOSDAQ:174900)

Market Cap	203.34B
Revenue (ttm)	2.32B
Net Income (ttm)	-16.77B
Shares Out	19.09M
EPS (ttm)	-970.22
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	47,268
Average Volume	77,878
Open	10,790
Previous Close	10,650
Day's Range	10,650 - 10,930
52-Week Range	6,810 - 18,100
Beta	0.66
RSI	40.16
Earnings Date	n/a

About AbClon

AbClon Inc. engages in the research and development of antibody drugs in South Korea and Sweden. The company’s products in pipeline include NEST platform technology products for breast and gastric cancers; AffiMab platform technology products for colon cancer and autoimmune diseases; and CAR-T platform technology products for hematologic and ovarian cancers. AbClon Inc. was founded in 2010 and is based in Seoul, South Korea.

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2010
• Country: South Korea
• Stock Exchange: KOSDAQ
• Ticker Symbol: 174900

Financial Performance

In 2024, AbClon's revenue was 2.34 billion, a decrease of -18.67% compared to the previous year's 2.88 billion. Losses were -16.42 billion, 27.2% more than in 2023.